Positive News Sentiment NASDAQ:SRPT Sarepta Therapeutics - SRPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $120.71 -4.26 (-3.41%) (As of 02/1/2023 01:14 PM ET) Add Compare Share Share Today's Range$120.32▼$125.4850-Day Range$114.57▼$132.1352-Week Range$61.28▼$134.08Volume274,958 shsAverage Volume1.00 million shsMarket Capitalization$10.60 billionP/E RatioN/ADividend YieldN/APrice Target$150.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside21.8% Upside$150.14 Price TargetShort InterestHealthy7.03% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment1.64Based on 6 Articles This WeekInsider TradingSelling Shares$94,311 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.07) to ($3.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.43 out of 5 starsMedical Sector211th out of 1,053 stocksPharmaceutical Preparations Industry91st out of 519 stocks 3.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $150.14, Sarepta Therapeutics has a forecasted upside of 21.8% from its current price of $123.25.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.03% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 9.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 3.1 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sarepta Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,311.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions87.31% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($8.07) to ($3.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -15.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -15.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 11.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics (NASDAQ:SRPT) StockSarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.Read More Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comMD gene therapy invented at Nationwide Children's could hit $4B annual sales if approvedJanuary 26, 2023 | finance.yahoo.com7 Biotech Stocks That Will Make You Rich in 10 YearsFebruary 1, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.January 21, 2023 | reuters.comSRPT.MW - | Stock Price & Latest News | ReutersJanuary 20, 2023 | markets.businessinsider.com9 Analysts Have This to Say About Sarepta TherapeuticsJanuary 10, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)January 9, 2023 | finance.yahoo.comSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product RevenuesJanuary 8, 2023 | finance.yahoo.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near FutureFebruary 1, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.January 6, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)January 5, 2023 | thestreet.comSarepta Therapeutics (SRPT) Stock Soars Following Positive Meeting With FDAJanuary 3, 2023 | finance.yahoo.comSarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | thestreet.comSarepta Therapeutics (SRPT) Stock Jumps on Possibility of New Drug ApprovalDecember 22, 2022 | msn.comBTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To KnowNovember 30, 2022 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)November 29, 2022 | finance.yahoo.comSarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority ReviewNovember 28, 2022 | marketwatch.comSarepta Gets FDA Priority Review for SRP-9001 in Duchenne Muscular Dystrophy >SRPTNovember 28, 2022 | nasdaq.comSarepta: FDA To Review BLA For SRP-9001 - Quick FactsNovember 28, 2022 | barrons.comSarepta’s Gene Therapy Set for Quick FDA ReviewNovember 28, 2022 | finance.yahoo.comSarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular DystrophyNovember 28, 2022 | finance.yahoo.comSarepta expected to get FDA decision on Duchenne treatment by May 29November 28, 2022 | finance.yahoo.comSarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene TherapyNovember 23, 2022 | finance.yahoo.comSarepta Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNovember 21, 2022 | barrons.comPremarket Movers: Disney, Coinbase Global, Sarepta TherapeuticsNovember 4, 2022 | benzinga.comSarepta Therapeutics Unusual Options ActivityNovember 4, 2022 | finance.yahoo.comSarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag EstimatesNovember 2, 2022 | msn.comSarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Company Calendar Last Earnings11/03/2021Today2/01/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees840Year Founded1980Price Target and Rating Average Stock Price Forecast$150.14 High Stock Price Forecast$190.00 Low Stock Price Forecast$114.00 Forecasted Upside/Downside+24.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($8.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-418,780,000.00 Net Margins-81.76% Pretax Margin-81.11% Return on Equity-97.37% Return on Assets-23.18% Debt Debt-to-Equity Ratio3.58 Current Ratio4.36 Quick Ratio3.99 Sales & Book Value Annual Sales$701.89 million Price / Sales15.10 Cash FlowN/A Price / Cash FlowN/A Book Value$10.66 per share Price / Book11.32Miscellaneous Outstanding Shares87,780,000Free Float82,165,000Market Cap$10.60 billion OptionableOptionable Beta1.04 Social Links Key ExecutivesDouglas S. IngramPresident, Chief Executive Officer & DirectorIan M. EstepanExecutive VP, Chief Financial & Accounting OfficerLouise Rodino-KlapacChief Scientific Officer & Executive VPBilal ArifChief Technical Operations OfficerDallan MurrayChief Customer Officer & Senior Vice PresidentKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVAJazz PharmaceuticalsNASDAQ:JAZZUnited TherapeuticsNASDAQ:UTHRCatalentNYSE:CTLTLegend BiotechNASDAQ:LEGNView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundBought 1,000 shares on 1/30/2023Ownership: 0.104%Advisory Alpha LLCSold 185 shares on 1/30/2023Ownership: 0.003%Peak Asset Management LLCBought 1,720 shares on 1/30/2023Ownership: 0.002%Howland Capital Management LLCBought 1,632 shares on 1/30/2023Ownership: 0.002%Beacon Capital Management LLCSold 89 shares on 1/27/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions SRPT Stock - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price forecast for 2023? 9 Wall Street research analysts have issued 1 year price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $114.00 to $190.00. On average, they predict the company's share price to reach $150.14 in the next year. This suggests a possible upside of 20.1% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2023? Sarepta Therapeutics' stock was trading at $129.58 at the start of the year. Since then, SRPT stock has decreased by 3.6% and is now trading at $124.97. View the best growth stocks for 2023 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.86) by $1.26. The biotechnology company earned $189.41 million during the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 97.37% and a negative net margin of 81.76%. During the same quarter last year, the firm earned ($2.50) EPS. What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.83%), Allspring Global Investments Holdings LLC (0.43%), National Bank of Canada FI (0.34%), Pinnacle Associates Ltd. (0.11%), New York State Common Retirement Fund (0.10%) and Comerica Bank (0.09%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $124.97. How much money does Sarepta Therapeutics make? Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.97 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($8.21) on an earnings per share basis. How many employees does Sarepta Therapeutics have? The company employs 840 workers across the globe. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038. This page (NASDAQ:SRPT) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.